Aug 8, 2024 · Sunitinib is used to treat certain types of advanced or progressive tumors of the stomach, intestines, esophagus, pancreas, or kidneys. Sunitinib may also be used for purposes not listed in this medication guide.

Sunitinib 50 Mg Capsule Antineoplastic - Protein-Tyrosine Kinase Inhibitors - Uses, Side Effects, and More Common Brand(S): Sutent Generic Name(S): sunitinib malate

Aug 9, 2024 · Use: For the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in patients with unresectable locally advanced or metastatic disease. Mild, moderate or severe renal impairment: No dose adjustment is recommended.

Mar 1, 2025 · Adults—50 milligrams (mg) once a day for 4 weeks. This is followed by 2 weeks without medicine for nine 6-week cycles. Your doctor may adjust your dose as needed and tolerated.

SUTENT is indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable locally advanced or metastatic disease. 2 DOSAGE AND ADM INISTRATION

Oct 9, 2024 · Sunitinib is used in the treatment of kidney cancer and gastrointestinal stromal tumour. Sunitinib is an anti-cancer medication. It works by binding and blocking certain cell surface protein (tyrosine kinase) responsible for the propagation of cancer growth. It also restricts the growth of new blood vessels within the tumor.

What Is Sunitinib and How Does It Work? Sunitinib is a prescription medication indicated for the treatment of advanced or progressive tumors of the stomach, intestines, esophagus, pancreas, or kidneys. What Are Dosages of Sunitinib? Adult dosage. Capsule. Gastrointestinal Stromal Tumor. Adult dosage. Renal Cell Carcinoma. Adult dosage.

Find patient medical information for Sutent oral on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings.

Jan 31, 2025 · Sunitinib malate capsules are supplied as printed hard shell capsules containing 12.5 mg, 25 mg, 37.5 mg or 50 mg of sunitinib (equivalent to 16.7 mg, 33.4 mg, 50.1 mg, or 66.8 mg of sunitinib malate, respectively). The capsules contain the following inactive ingredients: croscarmellose sodium, magnesium stearate, mannitol, and povidone K-30.

Indicated for treatment of gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. 50 mg PO qDay for 4 weeks, THEN 2 weeks drug-free, repeat...